What is Global Female Sexual Dysfunction Treatment Market?
The Global Female Sexual Dysfunction Treatment Market is a specialized sector of the healthcare industry that focuses on providing solutions for women suffering from sexual dysfunction. This market encompasses a wide range of treatments, including pharmaceuticals, therapies, and devices, designed to address various types of sexual dysfunction in women. These dysfunctions can range from lack of sexual desire, difficulty in becoming aroused, inability to achieve orgasm, to pain during sexual intercourse. The market is driven by the increasing awareness about female sexual health and the growing prevalence of sexual dysfunction among women globally. It is also influenced by the ongoing research and development activities aimed at introducing innovative and effective treatments for female sexual dysfunction. The market is further segmented based on the type of treatment, the type of dysfunction, and the region.
Non-hormonal Therapy, Hormonal Therapy in the Global Female Sexual Dysfunction Treatment Market:
The Global Female Sexual Dysfunction Treatment Market offers two main types of treatments: Non-hormonal Therapy and Hormonal Therapy. Non-hormonal therapy includes treatments that do not involve the use of hormones. These can include psychological counseling, physical therapy, and the use of certain medications that can help improve sexual function. On the other hand, Hormonal Therapy involves the use of hormones to treat sexual dysfunction. This can include the use of estrogen, testosterone, and other hormones that can help balance the hormonal levels in the body and improve sexual function. The choice between non-hormonal and hormonal therapy depends on the specific type of sexual dysfunction, the underlying cause, and the individual patient's health condition and preferences.
Sexual Desire Disorders, Sexual Arousal Disorders, Orgasm Disorders, Sexual Pain Disorders, Post-orgasmic Diseases, Pelvic Floor Dysfunction, Other in the Global Female Sexual Dysfunction Treatment Market:
The Global Female Sexual Dysfunction Treatment Market caters to a wide range of sexual dysfunctions. These include Sexual Desire Disorders, which involve a lack of sexual desire or interest in sex; Sexual Arousal Disorders, which involve difficulty in becoming sexually aroused; Orgasm Disorders, which involve difficulty in achieving orgasm; Sexual Pain Disorders, which involve pain during sexual intercourse; Post-orgasmic Diseases, which involve symptoms that occur after orgasm; Pelvic Floor Dysfunction, which involves problems with the muscles of the pelvic floor; and Other sexual dysfunctions that do not fit into these categories. Each of these dysfunctions requires a different approach to treatment, and the market offers a wide range of options to cater to these diverse needs.
Global Female Sexual Dysfunction Treatment Market Outlook:
The Global Female Sexual Dysfunction Treatment Market has shown significant growth in recent years. In 2023, the market was valued at US$ 122.6 million. However, it is expected to reach a staggering US$ 819.4 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 30.6% during the forecast period from 2024 to 2030. This growth is much higher than the overall growth of the global pharmaceutical market, which is estimated to be 1475 billion USD in 2022, growing at a CAGR of 5% over the next six years. Similarly, the chemical drug market is expected to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The rapid growth of the Female Sexual Dysfunction Treatment Market can be attributed to the increasing awareness about female sexual health and the growing prevalence of sexual dysfunction among women globally.
| Report Metric | Details |
| Report Name | Female Sexual Dysfunction Treatment Market |
| Accounted market size in 2023 | US$ 122.6 million |
| Forecasted market size in 2030 | US$ 819.4 million |
| CAGR | 30.6% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | AMAG Pharmaceuticals Inc., Duchesnay Inc., Emotional Brain BV, Novo Nordisk AS, Sprout Pharmaceuticals Inc. |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
